This website contains promotional content and is intended for Healthcare Professionals based in the United States only.
Factor VIII (FVIII) replacement therapies have been a step forward for the prevention and treatment of bleeding episodes in patients with hemophilia A. One remaining challenge is the development of neutralizing antibodies, known as inhibitors, which interfere with patient response to a factor infusion or render it ineffective.
Hemophilia A–a rare bleeding disorder–often goes undiagnosed in women because of the misconception that it only affects men, due to its X-linked recessive inheritance pattern. Although factor levels above 50% are usually considered within the normal range, emerging data suggest that some women and girls with levels between 50% and 60% may still have an increased risk of bleeding symptoms. Additionally, they may have sex-specific symptoms such as heavy menstrual bleeding and postpartum hemorrhage. This highlights the need for a more nuanced understanding of hemophilia A as it pertains to women.
Respiratory syncytial virus (RSV) transmission is high, especially among young children and infants.1 The incubation period for RSV varies, typically ranging from a few days to a week, before symptoms begin to manifest.2,3
MAT-US-2405607-v1.0-06/2024
